Jaguar Health, Inc. (NASDAQ:JAGX) stock is thriving today as it soared over 44% to reach $3.8 as it revealed in an announcement that the 28-day preclinical test in dogs has begun, January 6, 2021, to support the development of lechlemer, the plant-based drug candidate of Jaguar Health’s wholly-owned subsidiary, Napo Pharmaceuticals, for the relief of diarrhea from cholera.
The National Institute of Allergy and Infectious Diseases will provide preclinical services to Napo to support lechlemer development. The NIAID-funded contractors conducting the 28-day dog study are part of NIAID’s suite of preclinical services. NIAID is a division of the National Institutes of Health.
According to the Company, lechlemer, which is significantly less costly than crofelemer, has a similar mechanism of action and may support development efforts to receive a priority review voucher from the FDA to indicate the treatment of diarrhea associated with cholera. The FDA grants priority review vouchers to treat neglected diseases and rare pediatric diseases to incentivize treatment development. Historically, Priority Review vouchers were sold for prices ranging from $67 million to $350 million in past sales by other companies. Further, the Company believes lechlemer represents a substantial potential opportunity as a second-generation anti-secretory drug in multiple gastrointestinal disease indications, particularly in resource-constrained regions. There are often drug requirements prices to decrease annually in such areas.
In cholera, the intestine is infected with the bacterium Vibrio cholerae, which causes diarrheal illness. According to the Centers for Disease Control and Prevention of the U.S. Department of Health & Human Services, there are an estimated 35 million cholera cases and more than 100,000 cholera-related deaths around the world each year, according to the Centers for Disease Control and Prevention of the U.S. Department of Health & Human Services. Infections of this type are sometimes mild or asymptomatic, but are also fatal sometimes.
The U.S. Food and Drug Administration considers Lechlemer, a drug candidate under botanical guidance.
Jaguar Health, Inc. is a pharmaceutical company focused on developing novel, sustainable, and non-opioid prescription drugs for people and animals with digestive disorders, in particular chronic, debilitating diarrhea. Investors in the Company seem to be getting optimistic about the Company stock after the above announcement.